Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines

Similar documents
Materials and Methods

Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission

Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: a review

Cedivac-FMD; Duration of Immunity in cattle, sheep and pigs. 2004, 8203 AA Lelystad, The Netherlands * Corresponding Author

Longevity of protection in cattle following vaccination with emergency FMD vaccines from the UK strategic reserve

Lelystad, The Netherlands

Appendix 71 Secretory IgA as an indicator of oropharyngeal FMDV replication Abstract Introduction Materials and methods

Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the carrier state in sheep

Regulation of FMD vaccines within the European Union

FAO Collaborative Study Phase XVII: Standardisation of FMD Antibody Detection

A solid-phase competition ELISA for measuring antibody to foot-and-mouth disease virus

Manufacturers expected contribution to the progressive control of Foot-and-Mouth Disease in South Asia

Key words: foot-and-mouth disease; single emulsion vaccine, saponin, immune response, emergency vaccines.

COMPARISON OF DIFFERENT ELISA METHODS FOR THE DETECTION OF ANTIBODIES AGAINST FOOT-AND-MOUTH DISEASE VIRUS (FMDV) TYPE O

High potency vaccines induce protection against heterologous challenge with FMD virus

Appendix 30. Preliminary results to evaluate cross-protection between O 1 Manisa and O 1 Campos in cattle

Appendix 53 Addition of saponin to double oil emulsion FMD vaccines enhances specific antibody responses in cattle and pigs Introduction:

FMD vaccination and postvaccination. guidelines. Samia Metwally (FAO) Animal Production and Health Division FAO of the United Nations Rome, Italy

Chapter 6. Foot and mouth disease virus transmission during the incubation period of the disease in piglets, lambs, calves, and dairy cows

Dissecting Immune Responses. Miriam Windsor, Nicholas Juleff, Mandy Corteyn, Pippa Hamblin, Veronica Carr, Paul V Barnett, Bryan Charleston*

FMD Vaccine Strain Selection

Testing the Antibody Response of Pigs to Foot-and- Mouth Disease Vaccines

FMD VACCINE AND VACCINATION. Ahmad Al-Majali Dean, Faculty of Vet Medicine JUST Jordan

INTERNATIONAL STANDARDS FOR VACCINE BANKS

FOOT AND MOUTH DISEASE DIAGNOSTICS: REQUIREMENTS FOR DEMONSTRATION OF FREEDOM FROM INFECTION

DIFFERENTIATION OF INFECTION FROM VACCINATION BY DETECTION OF ANTIBODIES TO THE NON-STRUCTURAL PROTEIN 3ABC OF FOOT-AND-MOUTH DISEASE VIRUS

Detection of Foot-and-Mouth Disease Virus-Infected Cattle by Assessment of Antibody Response in Oropharyngeal Fluids

Importance of cell mediated immunity for protection against Foot and Mouth Disease

Field study conducted in Tunisia to evaluate efficacy of an O-BFS vaccine

QUANTITIES OF INFECTIOUS VIRUS AND VIRAL RNA RECOVERED FROM SHEEP AND CATTLE EXPERIMENTALLY INFECTED WITH FOOT-AND-MOUTH DISEASE VIRUS O UK 2001

1. Engineering Foot-and-Mouth Disease Viruses with Improved

REPORT ON THE SITUATION OF FMD IN TURKEY

Engineering Foot-and-Mouth Disease Virus with Improved Properties for the Development of Effective Vaccine Introduction: Materials and methods:

Alex I Donaldson. Institute for Animal Health, Pirbright, Woking, Surrey GU24 ONF, England

Appendix 68 3 ABC ELISA for the diagnosis of FMD in Egyptian sheep Abstract Introduction

FMD in Libya. Dr. Abdunaser Dayhum National Center of Animal Health Libya

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

This CRP is proposed for five years with three RCM. To apply, please see our website for directions:

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Immunity and how vaccines work

Points to consider in the prevention, control and eradication of FMD Dr. Paul Sutmoller* and Dr. Simon Barteling**

Foot and Mouth Disease Middle East situation Summary of Answers to the Questionnaire Beirut, Lebanon, 7 9 April 2009

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Foot and mouth disease situation and control strategies in the People s Republic of China the current situation

SCIENTIFIC DISCUSSION

PROGRESS REPORT FOR TURKEY ON FMD SITUATION AND CONTROL MEASURES

FMD Carrier state and role of carrier buffalo as source of transboundary spread in Southeast Asia and Eastern Asia Satya Parida

Using chloroform as a preservative for trivalent foot and mouth disease vaccine in comparison to thiomersal

FMD in Great Britain (Surrey)

Appendix 72 Using NSP ELISA (Chekit-FMD-3ABC Bommeli-Intervet) as a Tool for FMDV Serosurveillance in Bulgaria Abstract: Introduction

Foot and Mouth Disease Control, A vaccine perspective. John Barlow, DVM PhD

SEROLOGICAL EVALUATION OF THE IMMUNITY INDUCED IN COMMERCIAL RABBITS BY VACCINATION FOR MYXOMATOSIS AND RHD

Serological tests for foot-and-mouth disease in bovine serum samples. Problems of interpretation

Importance of Vaccines for Managing FMD

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

INTERNATIONAL WORKSHOP BLUETONGUE VACCINES 19 February 2013, Strasbourg, France ABSTRACTS

Dr Ghazi Yehia OIE Regional Representative for the Middle East

Foot and Mouth Disease Vaccine Research and Development in India

Foot and mouth disease vaccination and post-vaccination monitoring. Guidelines. Editors Samia Metwally Susanne Münstermann

Foot and mouth disease vaccination and post-vaccination monitoring. Guidelines. Editors Samia Metwally Susanne Münstermann

Simultaneous immunization of cattle with FMD and live anthrax vaccines

EPIDEMIOLOGICAL DEVELOPMENTS AND CONTROL OF FOOT AND MOUTH DISEASE IN ASIA

Progress report on the EUFMD supported actions in FMD Control in the Republic of Azerbaijan. Leos Celeda, Chairman EUFMD

Requirements for improved vaccines against foot-and-mouth disease epidemics

Comparative Studies of the Potency of Foot and Mouth Disease Virus Trivalent Vaccine with Different Concentration of the Antigenic Content (146S).

Ash Road, Woking, Surrey, GU24 0NF, UK.

Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011

ZOETIS ARE PROUD TO SUPPORT THE JOINT ACTION AGAINST BLUETONGUE CAMPAIGN

The administration of foot and mouth disease vaccine with oil adjuvant and its influence on the diagnosis of bovine tuberculosis

Chapter 5b. RT-PCR tests on tonsils of foot and mouth disease virus infected piglets at least four weeks after initial challenge

Foot and Mouth Disease vaccination is effective: Quantification of FMD transmission with and without vaccination

Requirements of the Terrestrial Code for FMD surveillance. Dr David Paton Dr Gideon Brückner

Excretion of bluetongue virus in cattle semen: a feature of laboratory-adapted virus

Overview of WRL FMD. Historical perspective. Principal activities. FMD threats. Needs/prospects. David Paton

Elements of the FMD control problem in Southern Africa: 2

Soren Alexandersen, Ian Brotherhood and Alex I. Donaldson. Institute for Animal Health, Pirbright Laboratory, Pirbright, Woking, Surrey, GU24 ONF, UK.

SPECIFIC ANTIINFECTIOUS IMMUNITY. colostral immunity. administration of antibodies VIRULENT VACCINE INACTIVATED VACCINE

Bovine Herpes Virus type 1 (BoHV-1), strain Difivac (ge-negative), to induce a geometric mean seroneutralizing titre of at least 1:160 in cattle

Foreign Animal Disease Research Unit USDA/ARS

Progressive Control of Foot and Mouth Disease in PAKISTAN

Country Report on FMD in Uganda

Open to: Model developers and users with an interest in the objective

Innate immune responses following emergency vaccination against foot-and-mouth disease virus in pigs

GLOBAL FMD SITUATION DURING 2001/2002

Foot and Mouth Disease

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

Immune responses in pigs and cattle vaccinated with half-volume foot-and-mouth disease vaccine

Scientific discussion

ASEAN STANDARDS FOR ANIMAL VACCINES

Foot-and Mouth Disease Ecological Studies In Endemic Settings: Ongoing Studies in Vietnam and Pakistan

The Global control of FMD - Tools, ideas and ideals Erice, Italy October 2008

Strengthening FMD prevention and emergency response capacity in the Trans-Caucasian countries (MTF/INT/003/EEC)

FMD Summary Epidemiology Report Situation as at 10:00 Thursday 09 August

Gripovac 3 is an inactivated, adjuvanted vaccine intended for active immunisation of pigs against disease caused by Swine Influenza Virus.

The inhibition of FMD virus excretion from the infected pigs by an antiviral agent, T-1105

Questionnaire results

Mechanism of FMD spread in East Asia

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Moving towards a better understanding of airborne transmission of FMD

Prophylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge

Transcription:

247 Appendix 31 Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines S. J Cox and P. V. Barnett Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Surrey GU24 0NF, U.K. Summary Ideal vaccines should be capable of stimulating a potent and long-lasting immunity, after a single vaccination. Conventional FMD vaccines, however, require frequent re-vaccinations to maintain antibody at protective levels. Consequently the search for more effective FMD vaccines continues to occupy research teams world-wide. Studies using high potency emergency FMD vaccines, particularly those incorporating the ready-to-formulate oil adjuvant Montanide ISA 206, have shown not only rapid sero-conversion but maintenance of a protective antibody response for at least 6 months in sheep and 4.7 months in pigs, after a single vaccination. Such long-lasting immunity, which is likely to overcome the need to revaccinate, would be invauable in the control of an FMD outbreak. These high potency vaccines are worthy of further investigation, to monitor exactly how long protective immunity can be maintained following a single application, as this may provide not only benefits for the control procedures used in FMD-free countries but also a more efficient and cost effective means of maintaining herd immunity in endemic areas. Introduction Much research and effort has been directed towards the improvement of vaccines to FMD and to the understanding of host immune responses to natural FMD infection in order to develop vaccines which promote potent long lasting immunity ( as reviewed by Barteling and Vreeswijk, 1991, Doel, 1991, 1996). However, depending on type and quality, the widely used conventional, low potency FMD vaccine formulations are often unable to provide an immunity that lasts longer than 6 months. Consequently livestock need to be revaccinated, depending upon the epidemiological situation, between one and three times a year for protection to be maintained. Ruminants require a primary vaccination followed by a booster vaccination at 3-4 weeks. Pigs generally only require a single dose of oil adjuvanted vaccine, which can result in a long duration of immunity (Anderson et al., 1971), but more often they require boosting at approximately 6 monthly intervals. The main requirements of emergency vaccines are to rapidly induce protective immunity and reduce local virus replication thus limiting virus spread and transmission during an outbreak of FMD. In recent years, studies at the International Vaccine Bank (IVB), located at IAH Pirbright laboratory, using cattle (Doel et al., 1994, Salt et al., 1995), pigs (Salt et al., 1997) and sheep (Cox et al., 1999), have provided much data confirming the ability of such vaccines to prevent disease and transmission of FMDV. These studies, however, were interested in early immune events and were frequently terminated after 28 days so that the duration of the response remained unknown. As the need for a vaccine for both ruminants and pigs that confers long lasting immunity, ideally after a single vaccination remains, several recent additional studies have been performed using the same emergency vaccine

248 formulations to investigate the longevity of the antibody response in sheep and pigs. In sheep, both oil and aqueous vaccine formulations were investigated where as the pig study evaluated the total neutralising antibody and some of the different classes of antibody present following vaccination with oil adjuvanted vaccine. Materials and methods Vaccine formulations incorporating FMDV O 1 Lausanne or C 1 Oberbayern inactivated antigen as a water-in-oil-in-water (W/O/W) emulsion with Montanide ISA 206 (Seppic, Paris) were used in pigs. Studies in sheep used formulations incorporating FMDV O 1 Manisa and A 22 Iraq inactivated antigen as W/O/W or oil-in-water (O/W) emulsions with either Montanide ISA 206 or ISA 25 (Seppic, Paris) respectively or an aqueous (Al/OH 3 )/saponin formulation. All the vaccines were prepared from antigen concentrates held currently by the IVB over liquid nitrogen and are highly potent with PD 50 values of 41, 112, 112 and 75 for O 1 Lausanne, C 1 Oberbayern, O 1 Manisa and A 22 Iraq respectively when tested as an Al(OH) 3 /saponin formulation. All vaccines used in sheep were administered as a 1.0ml volume (equivalent to half of a bovine dose), by the intramuscular route (W/O/W and O/W vaccines) into the right quadriceps mass or subcutaneously (aqueous vaccine) over the left shoulder. Pigs received a 2.0ml volume (equivalent to 1 bovine dose) by the intramuscular route immediately caudal to the ear. Groups of three Large White crossbred Landrace pigs weighing 20-30 kg or three polled Dorset Horn sheep aged between 6 and 12 months were immunised with vaccines as detailed above. All animals were monitored daily for temperature and well-being for 10 days following vaccination and bled regularly for serology up to 141 days (pigs) and 168 days (sheep) post vaccination. Neutralising antibody titres against FMDV in serum were measured by a microneutralisation assay, essentially as detailed by Golding et al. (1976). End-point titres were calculated as the reciprocal of the last serum dilution to neutralise 100 TCID 50 of homologous FMDV in 50% of the wells. An antibody isotype analysis of the pig sera was performed using an ELISA (IDAS) as described by Salt et al. (1996). Anti porcine isotype reagents (anti IgM, IgG1, IgG2 and IgA) were supplied by Serotec, UK. Results Temperatures remained normal and no side effects were recorded following vaccination with either the aqueous or oil formulations in the relevant target species. Neutralising antibody responses for sheep vaccinated with A 22 Iraq and O 1 Manisa over 168 days are shown in figure 1. All animals had seroconverted by seven days post vaccination, regardless of adjuvant, and in most animals titres had peaked within 28 days. The sheep vaccinated with Montanide ISA 206 oil formulation (fig 1, c and f ) maintained high titres of antibody for the duration of the trial, particularly for the A 22 Iraq vaccine. However, responses for the vaccines formulated with either Al(OH) 3 /saponin (fig 1, a and d) or Montanide ISA 25 (fig 1, b and e) demonstrated a gradual decline from peak antibody titres which leveled off after 66 days for most individuals. Neutralising antibody titres for pigs vaccinated with either O 1 Lausanne or C 1 Oberbayern are shown in figure 2. All pigs had seroconverted by seven days post vaccination with peak titres generally being evident between 21 and 28 days post vaccination. Antibody isotype analyses of sera from pigs vaccinated with either of the two serotypes demonstrated typical

249 profiles and are shown in figure 3. All animals responded to vaccination with a rapid IgM response which was prolonged in animals vaccinated with O 1 Lausanne. IgG 1 responses were generally earlier and reached higher titres than IgG 2. One animal (TX 89) appeared unable to mount an IgG 2 response and no IgA was detected from any animal at any point after vaccination. Conclusions Conventional aqueous vaccines in ruminants generally promote protective immunity within 8-10 days following primary vaccination and a secondary injection is required to maintain immunity at protective levels for about 6 months. Thereafter further re vaccinations at regular intervals, depending upon epidemiological situation, are required to maintain protective immunity. All the high potency vaccine preparations used in the sheep study generated a rapid antibody response (confirming previous observations, Cox et al., 1999) and in most sheep the antibody titres were maintained, at levels considered protective, for the duration of the study. The sheep vaccinated with A 22 Iraq serotype responded particularly well following vaccination with all three formulations although sheep vaccinated with the Montanide ISA 206 oil formulation were the only group to maintain peak titres for the duration of the trial. Peak antibody titres in the sheep vaccinated with O 1 Manisa vaccine formulations were less dramatic and more variable but again the Montanide ISA 206 oil formulated vaccine gave the best results. However, since the A 22 Iraq vaccine formulations gave a better response than the O 1 Manisa formulations but had originally shown lower potency as an aqueous formulation ( 75 and >112 respectively in cattle), maintenance of the response cannot relate entirely to this or indeed the payload of antigen per dose (1.246 and 2.394 for A 22 Iraq and O 1 Manisa respectively). Variation between serotypes which display differing levels of immunogenicity will inevitably contribute to the magnitude of the response (Doel.,1996). Since the sheep only received a single injection of vaccine these results suggest that higher potency vaccines may offer advantages over conventional aqueous vaccines particularly the oil adjuvanted formulations. Oil adjuvanted vaccines of various types have previously been shown to promote good protection in ruminants and pigs with immunity lasting for more than six months (reviewed Barteling & Vreeswijk, 1991). Depending on the formulation used, conventional oil adjuvanted vaccines that are used in pigs normally only require a single injection to promote a protective immunity which develops within approximately 8 days and lasts for about 6 months. Our study with C 1 Oberbayern and O 1 Lausanne Montanide ISA 206 oil formulated vaccines show that high potency vaccines also promote neutralising antibody which is maintained at levels considered protective for at least 4.7 months and compare well with the level of protective immunity maintained in convalescent pigs following FMD infection (Doel., 1999). Highest titres were evident between 21 and 28 days which was later than had previously been observed (Barnett et al., 1996). Once peak titres had been achieved they were generally maintained although some minimal decline was evident in the antibody levels of those pigs vaccinated with the O 1 Lausanne formulation for the remainder of the trial period. Interestingly, Anderson et al (1971) observed similar antibody decline in pigs after vaccination with a single oil emulsion containing O 1 Swiss 1/66 but not with similar formulations containing an A or C serotype. Individual isotype-specific antibody responses were measured in the pig sera. As previously shown by Ouldridge et al. (1982), and typical of primary responses, a rapid IgM response was prominent 3-5 days following vaccination which peaked within 7 14 days post immunisation. IgG responses were only generally detected 9 or more days post-vaccination.

250 This may have implications with regard to the role of the antibody response and the early protective immunity achieved within 4 days of vaccination (Salt et al., 1997). Although innate parameters are felt likely to be involved in such rapid protection (Cox et al., 1999), the role of the antibody response cannot be dismissed. However, if antibody does have a function at the early stages following vaccination, then the isotype profiles seen in this study suggest that IgM and not IgG plays an important role in early protection. IgG 1 appears to be the first of the IgG isotypes detected which in most cases peaked around 28 days and was followed later by IgG 2 ( apart from pig TX 90 which appeared unable to mount an IgG 2 response). Levels of IgG 1 tended to be higher than IgG 2 which is consistent with previous reports for cattle ( Mulcahy et al., 1990) although the antibody isotypes of different species and there functions are not fully understood and therefore do not necessarily correlate with each other. Further studies are on going to monitor this primary response for 6-9 months following which the qualitative aspects of the response in terms of protection will be investigated. In conclusion, these preliminary investigations in sheep and pigs have suggested that oil adjuvanted high potency emergency vaccines provide not only a rapid immune response but also a long lasting immunity following a single application. Such attributes make them ideal for use in FMD-free countries where emergency ring vaccination may be necessary, as they are likely to overcome the need to re-vaccinate during an outbreak. Similar formulations would also be more efficient, and possibly more cost effective, for maintaining herd immunity in areas endemic for FMD by increasing the interval between re vaccinations. Acknowledgements This work was supported financially by MAFF, UK and EU (FAIR-PL97-3665). References Anderson, E.C, Masters, R.C and Mowat, G.N. (1971) Immune response of pigs to inactivated foot-and-mouth disease vaccines. Res. Vet. Sci. 12, 342-350. Barteling, S.J and Vreeswijk, J. (1991) Developments in foot-and-mouth vaccines. Vaccine 9, 75-88. Barnett, P.V, Pullen, L., Williams, L. and Doel, T.R. (1996). International bank for foot-andmouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants. Vaccine 14(13), 1187-1198. Cox, S.J., Barnett, P.V., Dani, P. and Salt, J.S. (1999) Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 17, 1858-68. Doel, T.R., Williams, L and Barnett, P.V. (1994) Emergency vaccination against foot-andmouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 12, 592-600.

251 Doel, T.R. (1996) Natural and vaccine-induced immunity to foot and mouth disease: the prospects for improved vaccines. Rev. sci. tech. Off. Int. Epiz. 15(3), 883-911. Doel, T.R (1999) Optimisation of the immune response to foot-and-mouth disease vaccines. Vaccine 17, 1767-1771. Golding, S.M., Hedger, R.S. & Talbot, P. (1976). Radial immuno-diffusion and serum neutralisation techniques for the assay of antibodies to swine vesicular disease. Res. Vet. Sci. 20, 142-147. Mulcahy, G., Gale, C., Robertson, P., Iyisan, S., DiMarchi, R.D. and Doel, T.R. (1990). Isotype responses of infected virus-vaccinated and peptide vaccinated cattle to foot-andmouth disease virus. Vaccine 8, 249-256. Ouldridge, E.J., Francis, M.J. and Black, L. (1982). Antibody response of pigs to foot-andmouth disease oil emulsion vaccine: the antibody classes involved. Res. Vet Sci. 32, 327-331. Salt, J.S, Williams, L., Statham, R and Barnett, P.V. (1995). Further studies on the rate of development of protection in cattle given emergency vaccination against FMD. Report of the session of the Standing Technical Committee of the European Commission for the Control of oot-and-mouth Disease, Moedling, Vienna, Austria, Appendix 17, 90-97. Salt, J.S., Mulcahy, G. & Kitching, R.P. (1996). Isotype-specific antibody responses to footand-mouth disease virus in sera and secretions of carrier and non-carrier cattle. Epidemiol. Infect. 117, 349-360. Salt, J.S., Barnett, P.V., Dani, P. and Williams, L. (1997) Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 16(7), 746-754.